Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes

Langan, 2008, Bullous pemphigoid and pemphigus vulgaris—incidence and mortality in the UK: population based cohort study., BMJ, 337, a180, 10.1136/bmj.a180

Joly, 2012, Incidence and mortality of bullous pemphigoid in France., J Invest Dermatol, 132, 1998, 10.1038/jid.2012.35

Bernard, 1995, Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions., Arch Dermatol, 131, 48, 10.1001/archderm.1995.01690130050009

Zillikens, 1995, Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany., Arch Dermatol, 131, 957, 10.1001/archderm.131.8.957

Kridin, 2018, Ethnic variations in the epidemiology of bullous pemphigoid in Israel., Int J Dermatol, 57, 34, 10.1111/ijd.2018.57.issue-1

Keseroglu, 2017, A case of bullous pemphigoid induced by vildagliptin., Cutan Ocul Toxicol, 36, 201, 10.1080/15569527.2016.1211670

Haber, 2016, Bullous pemphigoid associated with linagliptin treatment., JAMA Dermatol, 152, 224, 10.1001/jamadermatol.2015.2939

Mendonça, 2016, Three cases of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors–one due to linagliptin., Dermatology, 232, 249, 10.1159/000443330

Skandalis, 2012, Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin., J Eur Acad Dermatol Venereol, 26, 249, 10.1111/jdv.2012.26.issue-2

Béné, 2015, Bullous pemphigoid induced by vildagliptin: a report of three cases., Fundam Clin Pharmacol, 29, 112, 10.1111/fcp.2015.29.issue-1

Pasmatzi, 2011, Dipeptidyl peptidase-4 inhibitors cause bullous pemphigoid in diabetic patients: report of two cases., Diabetes Care, 34, e133, 10.2337/dc11-0804

Aouidad, 2013, A case report of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors., JAMA Dermatol, 149, 243, 10.1001/jamadermatol.2013.1073

Attaway, 2014, Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors: a case report and review of literature., J Dermatol Case Rep, 8, 24, 10.3315/jdcr.2014.1166

Béné, 2016, Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database., Br J Dermatol, 175, 296, 10.1111/bjd.14601

García, 2016, Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database., J Clin Pharm Ther, 41, 368, 10.1111/jcpt.12397

Benzaquen, 2018, Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case-control study from France and Switzerland., J Am Acad Dermatol, 78, 1090, 10.1016/j.jaad.2017.12.038

Varpuluoma, 2018, Vildagliptin significantly increases the risk of bullous pemphigoid: a Finnish nationwide registry study., J Invest Dermatol, S0022-202X(18)30110-6

Murrell, 2012, Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts., J Am Acad Dermatol, 66, 479, 10.1016/j.jaad.2011.06.032

Parker, 2008, Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States., J Am Acad Dermatol, 59, 582, 10.1016/j.jaad.2008.07.022

Lee, 2014, Mortality of patients with bullous pemphigoid in Korea., J Am Acad Dermatol, 71, 676, 10.1016/j.jaad.2014.05.006

Lai, 2016, Bullous pemphigoid and its association with neurological diseases: a systematic review and meta-analysis., J Eur Acad Dermatol Venereol, 30, 2007, 10.1111/jdv.13660

Schmidt, 2002, Subacute prurigo variant of bullous pemphigoid: autoantibodies show the same specificity compared with classic bullous pemphigoid., J Am Acad Dermatol, 47, 133, 10.1067/mjd.2002.120445

Lamb, 2006, Prodromal bullous pemphigoid., Int J Dermatol, 45, 209, 10.1111/ijd.2006.45.issue-3

Strohal, 1993, Nonbullous pemphigoid: prodrome of bullous pemphigoid or a distinct pemphigoid variant?, J Am Acad Dermatol, 29, 293, 10.1016/0190-9622(93)70179-W

Levine, 1979, Localized pemphigoid simulating dyshidrosiform dermatitis., Arch Dermatol, 115, 320, 10.1001/archderm.1979.04010030028010

Izumi, 2016, Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid., J Invest Dermatol, 136, 2201, 10.1016/j.jid.2016.06.622

Chijiwa, 2018, Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid., J Dermatol, 45, 596, 10.1111/jde.2018.45.issue-5

Gonzalez-Gronow, 2008, Dipeptidyl peptidase IV (DPP IV/CD26) is a cell-surface plasminogen receptor., Front Biosci, 13, 1610, 10.2741/2785

Hofmann, 2009, Plasmin plays a role in the in vitro generation of the linear IgA dermatosis antigen LADB97., J Invest Dermatol, 129, 1730, 10.1038/jid.2008.424

Forssmann, 2008, Inhibition of CD26/dipeptidyl peptidase IV enhances CCL11/eotaxin-mediated recruitment of eosinophils in vivo., J Immunol, 181, 1120, 10.4049/jimmunol.181.2.1120

Greenland, 2016, Sparse data bias: a problem hiding in plain sight., BMJ, 352, i1981, 10.1136/bmj.i1981